In summary, our findings demonstrate that sorafenib-treated HCC cells activate the FAK/AKT/HMGCR signaling axis, which promotes cholesterol biosynthesis and ultimately contributes to drug resistance. The gene discussed is AKT1; the disease is hepatocellular carcinoma.